If the Sinclair Method is so effective, why isn’t it standard practice everywhere?
Well, in places like Finland and parts of Europe — it kind of is.
The Numbers:
In Finland, over 50% of prescriptions for alcohol use disorder are for naltrexone. It’s not just an experimental treatment — it’s a mainstream, normalized option that doctors routinely offer.
Compare that to the U.S., where less than 5% of people with alcohol use disorder receive any medication-assisted treatment at all. And of that small fraction, most are prescribed older, less effective medications like disulfiram (Antabuse), which punishes drinking rather than controlling it.
In Finland, naltrexone is a first-line treatment, not a last resort. It’s recommended by doctors and often covered by national healthcare systems, making it accessible and affordable.
Why Europe Adopted It:
European countries tend to view alcohol use disorder through a public health lens, not a moral one.
The mindset isn’t, “You’re broken because you drink too much.”
It’s, “Let’s help you reduce harm and live a healthier life.”
This approach is called harm reduction. It focuses on minimizing the negative consequences of drinking — rather than insisting on total abstinence.
In countries like Finland, Norway, Sweden, and the U.K.:
- Doctors are trained in addiction science, including the proper use of naltrexone.
- Public health campaigns focus on safe drinking guidelines, not just prohibition.
- There’s less stigma around seeking help for alcohol problems.
Contrast this with the U.S., where alcohol use disorder is often framed as a moral failing. The default narrative is still:
- “You have to hit rock bottom.”
- “Quitting is the only option.”
- “If you’re still drinking, you’re in denial.”
This mindset creates barriers — not just for patients, but for doctors, insurers, and policymakers.
Meanwhile in the U.S.:
Here, medication-assisted treatment (MAT) is still seen as controversial or experimental.
- Many rehab centers don’t even offer naltrexone or train their staff in how to use it effectively.
- Insurance coverage for medications is often spotty or confusing.
- Even when patients ask about TSM, doctors may not know it exists, or they might prescribe naltrexone without understanding the crucial timing protocols.
Meanwhile, the rehab industry — a multi-billion-dollar sector — continues to push 12-step programs and abstinence-only models, which generate more recurring revenue from group meetings, intensive outpatient programs, and long-term clients.
Takeaway:
The science is already there. The evidence supporting the Sinclair Method is clear, and its effectiveness has been demonstrated in Finland and across Europe for years.
The problem?
In the U.S., the stigma and the entrenched, abstinence-focused recovery culture haven’t caught up yet.
But as more people learn about TSM, and as more stories emerge of success from around the world, the tide is beginning to turn.
It’s time to ask:
If Europe can embrace this science-based approach, why can’t we?